Letrozole

Letrozole is a medication that has been extensively studied in clinical trials for various medical conditions, primarily breast cancer and fertility treatments. This article summarizes key findings from several clinical trials investigating the use of letrozole in different contexts, providing insights into its effectiveness, safety, and potential applications.

Table of Contents

What is Letrozole?

Letrozole is a medication primarily used in the treatment of breast cancer. It belongs to a class of drugs called aromatase inhibitors. Letrozole is also known by the brand name Femara[1]. This medication is typically prescribed for postmenopausal women with a specific type of breast cancer known as hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer[1].

How Letrozole Works

Letrozole works by reducing the amount of estrogen in the body. It does this by blocking an enzyme called aromatase, which is responsible for producing estrogen. By lowering estrogen levels, letrozole can slow down or stop the growth of certain types of breast cancer cells that rely on estrogen to grow[2].

Conditions Treated with Letrozole

While letrozole is primarily used for breast cancer treatment, research is ongoing to explore its potential in treating other conditions. Here are the main conditions for which letrozole is used or being studied:

  • Advanced Breast Cancer: Letrozole is approved for treating postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer[1]. This type of breast cancer has receptors that are sensitive to hormones like estrogen, but does not have high levels of a protein called HER2 on the cancer cells.
  • Endometrial Cancer: Some studies are investigating the use of letrozole in treating advanced or recurrent endometrial cancer. Endometrial cancer is a type of cancer that begins in the lining of the uterus[3].
  • Ovarian Cancer: Research is being conducted to evaluate the effectiveness of letrozole in treating heavily pretreated recurrent ovarian cancer[4]. Ovarian cancer is a type of cancer that begins in the ovaries.

Dosage and Administration

Letrozole is typically taken orally in tablet form. The standard dosage for breast cancer treatment is 2.5 mg once daily[1]. It’s usually taken continuously, meaning you take it every day without breaks. Your doctor will determine the appropriate dosage and duration of treatment based on your specific condition and response to the medication.

Combination Therapies

In some cases, letrozole may be used in combination with other medications to enhance its effectiveness. One such combination that has been studied is letrozole with palbociclib (also known as PD-0332991 or Ibrance)[2]. Palbociclib is a drug that works by blocking certain proteins in cancer cells, potentially making letrozole more effective. This combination is being studied for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.

Side Effects and Safety

Like all medications, letrozole can cause side effects. Common side effects may include:

  • Hot flashes
  • Joint pain
  • Fatigue
  • Headache
  • Nausea

More serious side effects can occur, but they are less common. These may include an increased risk of osteoporosis (bone thinning) and cardiovascular events. Your doctor will monitor you closely for any side effects and adjust your treatment if necessary[2].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of letrozole in various settings:

  • Combination therapy with new drugs: Studies are exploring the combination of letrozole with newer drugs like PF-07220060 for breast cancer treatment[5].
  • Expanded access studies: These studies aim to provide access to letrozole for patients who might benefit from it but don’t qualify for other clinical trials[6].
  • Use in other cancers: As mentioned earlier, research is ongoing to evaluate the effectiveness of letrozole in endometrial and ovarian cancers[3][4].

It’s important to note that while these studies show promise, more research is needed to fully understand the potential benefits and risks of letrozole in these new applications.

Use of Letrozole Key Findings Dosage
Breast Cancer Treatment Effective as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer; various treatment durations studied (2-5+ years) 2.5 mg daily
Fertility Treatment Used for ovulation induction in IVF; may help maintain lower estrogen levels during stimulation 2.5-7.5 mg daily, depending on protocol
Neoadjuvant Therapy Studied in combination with other drugs (e.g., Avastin) for pre-operative treatment of breast cancer 2.5 mg daily
Uterine Leiomyosarcoma Under investigation for newly diagnosed stage I and II leiomyosarcoma 2.5 mg daily

Ongoing Clinical Trials on Letrozole

  • Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

    Not recruiting

    1 1 1
    Austria Belgium Denmark France Germany Greece +5
  • Study on Metformin to Prevent High Blood Sugar in Advanced Breast Cancer Patients with Alpelisib and Endocrine Therapy

    Not recruiting

    1 1 1
    Spain
  • Study on Ribociclib, Alpelisib, and Letrozole for Adults with Advanced Hormone Receptor-Positive Breast Cancer

    Not recruiting

    1 1 1
    France Spain
  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    1 1 1
    France
  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    1 1 1 1
    France
  • Study of PF-07220060 and PF-07104091 with Endocrine Therapy for Patients with Advanced HR-positive HER2-negative Breast Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Bulgaria Czechia Spain
  • Study on Denosumab for Improving Semen Quality in Men with Non-Obstructive Azoospermia

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

    Not recruiting

    1 1 1
    Czechia Slovakia
  • Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

    Not recruiting

    1 1 1 1
    Austria Belgium France Germany Hungary Ireland +4
  • Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

    Not recruiting

    1 1 1
    Investigated diseases:
    France Germany Italy Portugal Spain

Glossary

  • Aromatase inhibitor: A type of drug that lowers estrogen levels in the body by blocking the enzyme aromatase, which is responsible for producing estrogen.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk of cancer recurrence.
  • Hormone receptor-positive breast cancer: A type of breast cancer that has receptors for estrogen or progesterone, making it responsive to hormone therapy.
  • In vitro fertilization (IVF): A complex series of procedures used to help with fertility or prevent genetic problems and assist with the conception of a child.
  • Ovulation induction: The stimulation of ovulation using medication, often used in fertility treatments.
  • Tamoxifen: A medication used to treat hormone receptor-positive breast cancer by blocking the effects of estrogen in breast tissue.
  • Disease-free survival: The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Neoadjuvant therapy: Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery.
  • Gonadotropins: Hormones that stimulate the ovaries or testes, often used in fertility treatments.
  • Estradiol: The primary form of estrogen in the human body, important in female reproductive health and development.

References

  1. https://clinicaltrials.gov/study/NCT02679755
  2. https://clinicaltrials.gov/study/NCT01740427
  3. https://clinicaltrials.gov/study/NCT00333086
  4. https://clinicaltrials.gov/study/NCT04421547
  5. https://clinicaltrials.eu/trial/study-of-pf-07220060-and-letrozole-for-postmenopausal-women-with-hr-positive-her2-negative-breast-cancer/
  6. https://clinicaltrials.gov/study/NCT02142868